Related Experiment Video
Updated: Aug 31, 2025
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
Published on: September 26, 2016
Research progress of bone-targeted drug delivery system on metastatic bone tumors
Beibei Hu1, Yongkang Zhang2, Guogang Zhang2
1College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, 26 Yuxiang Road, Shijiazhuang 050018, PR China; State Key Laboratory Breeding Base-Hebei Province, Key Laboratory of Molecular Chemistry for Drug, 26 Yuxiang Road, Shijiazhuang 050018, PR China.
Abstract:
Bone metastases are common in malignant tumors and the effect of conventional treatment is limited. How to effectively inhibit tumor bone metastasis and deliver the drug to the bone has become an urgent issue to be solved. While bone targeting drug delivery systems have obvious advantages in the treatment of bone tumors. The research on bone-targeted anti-tumor therapy has made significant progress in recent years. We introduced the related tumor pathways of bone metastases. The tumor microenvironment plays an important role in metastatic bone tumors. We introduce a drug-loading systems based on different environment-responsive nanocomposites for anti-tumor and anti-metastatic research. According to the process of bone metastases and the structure of bone tissue, we summarized the information on bone-targeting molecules. Bisphosphate has become the first choice of bone-targeted drug delivery carrier because of its affinity with hydroxyapatite in bone. Therefore, we sought to summarize the bone-targeting molecule of bisphosphate to identify the modification effect on bone-targeting. And this paper discusses the relationship between bisphosphate bone targeting molecular structure and drug delivery carriers, to provide some new ideas for the research and development of bone-targeting drug delivery carriers. Targeted therapy will make a more outstanding contribution to the treatment of tumors.
Insights
Targeting bone metastases requires effective drug delivery. Bisphosphonate-based carriers show promise for bone-targeted anti-tumor therapy, offering new strategies for cancer treatment.
Area of Science:
- Oncology
- Biomaterials Science
- Pharmacology
Background:
- Bone metastases are a common complication of malignant tumors with limited conventional treatment efficacy.
- Effective inhibition of tumor bone metastasis and targeted drug delivery to bone are critical unmet clinical needs.
- Bone-targeting drug delivery systems offer significant advantages for treating bone tumors.
Purpose of the Study:
- To review tumor pathways involved in bone metastasis.
- To introduce environment-responsive nanocomposite drug-loading systems for anti-tumor and anti-metastatic research.
- To summarize bone-targeting molecules, focusing on bisphosphonates and their structural modifications for enhanced bone targeting.
Main Methods:
- Review of tumor metastasis pathways and the tumor microenvironment's role.
- Introduction of drug-loading systems utilizing environment-responsive nanocomposites.
- Summary and analysis of bone-targeting molecules, particularly bisphosphonates, and their structure-activity relationships.
Main Results:
- Bisphosphonates exhibit strong affinity for hydroxyapatite in bone, making them ideal bone-targeting drug delivery carriers.
- Understanding the relationship between bisphosphonate structure and drug delivery carriers can guide the development of novel bone-targeting systems.
- Environment-responsive nanocomposites offer potential for targeted anti-tumor and anti-metastatic therapies.
Conclusions:
- Bone-targeting drug delivery systems, especially those utilizing bisphosphonates, are crucial for advancing bone tumor treatment.
- Further research into bisphosphonate modifications and their integration with advanced drug carriers can significantly improve therapeutic outcomes.
- Targeted therapy holds substantial promise for more effective cancer treatment, particularly for bone metastases.
